Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2012 Aug 23;4(2):107–116. doi: 10.2165/00151829-200504020-00004

Management of Influenza Virus Infections with Neuraminidase Inhibitors

Detection, Incidence, and Implications of Drug Resistance

Jennifer L McKimm-Breschkin 1,✉
PMCID: PMC7099216  PMID: 15813662

Abstract

Although influenza vaccination remains the primary method for the prevention of influenza, efficacy may be limited by a poor match between the vaccine and circulating strains and the poor response of elderly patients. Hence, there is an important role for antiviral therapy in the management of influenza. While amantadine and rimantadine have been available for the treatment of influenza in some countries for several years, they are only effective against influenza A viruses, they can have neurological and gastrointestinal adverse effects, and resistant virus is rapidly generated. Neuraminidase inhibitors, a new class of drug, are potent and specific inhibitors of all strains of influenza virus, and they have minimal adverse effects. The greatest benefit is seen in those patients presenting <30 hours after development of influenza symptoms, those with severe symptoms or those in high-risk groups. In addition to treatment of the infection, both drugs are effective prophylactically and have been shown to limit spread of infection in close communities, such as families and in nursing homes. No resistant virus strains have been isolated from normal individuals treated with zanamivir. Resistant virus can be isolated from approximately 1% of adults and 5% of paediatric patients with influenza treated with oseltamivir. However, infectivity of mutant viruses is generally compromised. Governments spend millions of dollars on influenza vaccination campaigns; however, once influenza virus is circulating in the community, vaccination cannot limit the spread of disease. A greater promotion of the use of neuraminidase inhibitors for the treatment and prevention of influenza could have a significant impact on limiting its spread. This could result in saving millions of dollars, not only in direct costs associated with medical and hospital care, but also significant savings in indirect costs associated with the loss of productivity at work, school and home environments. For the benefit of all communities, there needs to be a greater awareness of the symptoms of influenza and the efficacy of neuraminidase inhibitors in disease treatment.

Keywords: Influenza, Influenza Virus, Sialic Acid, Oseltamivir, Amantadine

References

  • 1.Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–86. doi: 10.1001/jama.289.2.179. [DOI] [PubMed] [Google Scholar]
  • 2.Nicholson KG, Wood JM, Zambon M. Influenza. Lancet. 2003;362:1733–45. doi: 10.1016/S0140-6736(03)14854-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ruest A, Michaud S, Deslandes S, et al. Comparison of the Directigen flu A+B test, the Quick Vue influenza test, and clinical case definition to viral culture and reverse transcription-PCR for rapid diagnosis of influenza virus infection. J Clin Microbiol. 2003;41:3487–93. doi: 10.1128/JCM.41.8.3487-3493.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Nicholson KG. Managing influenza in primary care. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science; 1999. [Google Scholar]
  • 5.Fleming DM. The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Commun Dis Public Health. 2000;3:32–8. [PubMed] [Google Scholar]
  • 6.Brocklebank JT, Court SD, McQuillin J, et al. Influenza-A infection in children. Lancet. 1972;II:497–500. doi: 10.1016/S0140-6736(72)91902-2. [DOI] [PubMed] [Google Scholar]
  • 7.Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. London: Blackwell Science Ltd; 1998. pp. 358–72. [Google Scholar]
  • 8.Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA. 1994;272:1661–5. doi: 10.1001/jama.1994.03520210045030. [DOI] [PubMed] [Google Scholar]
  • 9.von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993;363:418–23. doi: 10.1038/363418a0. [DOI] [PubMed] [Google Scholar]
  • 10.Palese P, Tobita K, Ueda M, et al. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology. 1974;61:397–410. doi: 10.1016/0042-6822(74)90276-1. [DOI] [PubMed] [Google Scholar]
  • 11.Colman PM, Ward CW. Structure and diversity of influenza virus neuraminidase. Curr Top Microbiol Immunol. 1985;114:177–255. doi: 10.1007/978-3-642-70227-3_5. [DOI] [PubMed] [Google Scholar]
  • 12.Aoki F. Amantadine and rimantadine. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science; 1995. pp. 457–76. [Google Scholar]
  • 13.Keyser LA, Karl M, Nafziger AN, et al. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med. 2000;160:1485–8. doi: 10.1001/archinte.160.10.1485. [DOI] [PubMed] [Google Scholar]
  • 14.Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol. 1992;176:119–30. doi: 10.1007/978-3-642-77011-1_8. [DOI] [PubMed] [Google Scholar]
  • 15.Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocom- promised adults. Clin Infect Dis. 1998;26:1418–24. doi: 10.1086/516358. [DOI] [PubMed] [Google Scholar]
  • 16.Grambas S, Bennett MS, Hay AJ. Influence of amantadine resistance mutations on the pH regulatory function of the M2 protein of influenza A viruses. Virology. 1992;191:541–9. doi: 10.1016/0042-6822(92)90229-I. [DOI] [PubMed] [Google Scholar]
  • 17.Houck P, Hemphill M, LaCroix S, et al. Amantadine-resistant influenza A in nursing homes: identification of a resistant virus prior to drug use. Arch Intern Med. 1995;155:533–7. doi: 10.1001/archinte.1995.00430050113012. [DOI] [PubMed] [Google Scholar]
  • 18.Ziegler T, Hemphill ML, Ziegler ML, et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis. 1999;180:935–9. doi: 10.1086/314994. [DOI] [PubMed] [Google Scholar]
  • 19.Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc. 1997;119:681–90. doi: 10.1021/ja963036t. [DOI] [PubMed] [Google Scholar]
  • 20.Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem. 2000;43:3482–6. doi: 10.1021/jm0002679. [DOI] [PubMed] [Google Scholar]
  • 21.Stoll V, Stewart KD, Maring CJ, et al. Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series. Biochemistry (Mosc) 2003;42:718–27. doi: 10.1021/bi0205449. [DOI] [PubMed] [Google Scholar]
  • 22.Kati WM, Montgomery D, Carrick R, et al. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob Agents Chemother. 2002;46:1014–21. doi: 10.1128/AAC.46.4.1014-1021.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Masuda T, Shibuya S, Arai M, et al. Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir. Bioorg Med Chem Lett. 2003;13:669–73. doi: 10.1016/S0960-894X(02)01039-9. [DOI] [PubMed] [Google Scholar]
  • 24.Honda T, Yoshida S, Arai M, et al. Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives. Bioorg Med Chem Lett. 2002;12:1929–32. doi: 10.1016/S0960-894X(02)00330-X. [DOI] [PubMed] [Google Scholar]
  • 25.Macdonald SJ, Watson KG, Cameron R, et al. Potent and long-acting dimeric inhibitors of influenza virus meuraminidase are effective at a once-weekly dosing regimen. Antimicrob Agents Chemother. 2004;48:4542–9. doi: 10.1128/AAC.48.12.4542-4549.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Doucette KE, Aoki FY. Oseltamivir: a clinical and pharmacological perspective. Expert Opin Pharmacother. 2001;2:1671–83. doi: 10.1517/14656566.2.10.1671. [DOI] [PubMed] [Google Scholar]
  • 27.McKimm-Breschkin JL. Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opin Pharmacother. 2002;3:103–12. doi: 10.1517/14656566.3.2.103. [DOI] [PubMed] [Google Scholar]
  • 28.McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs. 2001;61:263–83. doi: 10.2165/00003495-200161020-00011. [DOI] [PubMed] [Google Scholar]
  • 29.Cheer SM, Wagstaff AJ. Zanamivir: an update of its use in influenza. Drugs. 2002;62:71–106. doi: 10.2165/00003495-200262010-00004. [DOI] [PubMed] [Google Scholar]
  • 30.McNicholl IR, McNicholl JJ. Neuraminidase inhibitors: zanamivir and oseltamivir. Ann Pharmacother. 2001;35:57–70. doi: 10.1345/aph.10118. [DOI] [PubMed] [Google Scholar]
  • 31.Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir. Lancet. 2004;364(9436):759–65. doi: 10.1016/S0140-6736(04)16934-1. [DOI] [PubMed] [Google Scholar]
  • 32.Hoffken G, Gillissen A. Efficacy and safety of zanamivir in patients with influenza: impact of age, severity of infections and specific risk factors. Med Microbiol Immunol (Berl) 2002;191:169–73. doi: 10.1007/s00430-002-0140-3. [DOI] [PubMed] [Google Scholar]
  • 33.Murphy KR, Eivindson APK, Stein WJ, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin Drug Invest. 2000;20(5):337–45. doi: 10.2165/00044011-200020050-00005. [DOI] [Google Scholar]
  • 34.US Food and Drug Administration, Center for Drug Evaluation and Research. NDA21-087 Tamiflu (Oseltamivir Phosphate) capsule [online]. Available from URL: http://www.fda.gov/cder/foi/nda/99/21087_Tamiflu.htm [Accessed 2003 Aug 6]
  • 35.Johnson RJ, Schweinle JE, Burroughs S. Zanamivir for the treatment of clinically diagnosed influenza in clinical practice. Clin Drug Invest. 2000;20(5):327–36. doi: 10.2165/00044011-200020050-00004. [DOI] [Google Scholar]
  • 36.Diggory P, Fernandez C, Humphrey A, et al. Comparison of elderly people’s technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ. 2001;322:577–9. doi: 10.1136/bmj.322.7286.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Johnson RJ, Schweinle JE, Burroughs S. Zanamivir for the treatment of clinically diagnosed influenza in clinical practice. Clin Drug Invest. 2000;20(5):327–36. doi: 10.2165/00044011-200020050-00004. [DOI] [Google Scholar]
  • 38.Silagy C, Watts R. Zanamivir, a new targeted therapy in the treatment of influenza: a patient perspective assessed by questionnaire. Clin Drug Invest. 2000;19:111–21. doi: 10.2165/00044011-200019020-00004. [DOI] [Google Scholar]
  • 39.Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127–33. doi: 10.1097/00006454-200102000-00002. [DOI] [PubMed] [Google Scholar]
  • 40.Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240–6. doi: 10.1001/jama.282.13.1240. [DOI] [PubMed] [Google Scholar]
  • 41.Wooltorton E. Oseltamivir (Tamiflu) unsafe in infants under 1 year old. CMAJ. 2004;170:336. [PMC free article] [PubMed] [Google Scholar]
  • 42.McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and streptococcus pneumoniae. J Infect Dis. 2003;187:1000–9. doi: 10.1086/368163. [DOI] [PubMed] [Google Scholar]
  • 43.McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003;47:2264–72. doi: 10.1128/AAC.47.7.2264-2272.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Tumpey TM, Garcia-Sastre A, Mikulasova A, et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A. 2002;99:13849–54. doi: 10.1073/pnas.212519699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Leneva IA, Goloubeva O, Fenton RJ, et al. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother. 2001;45:1216–24. doi: 10.1128/AAC.45.4.1216-1224.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Leneva IA, Roberts N, Govorkova EA, et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 2000;48:101–15. doi: 10.1016/S0166-3542(00)00123-6. [DOI] [PubMed] [Google Scholar]
  • 47.CSIRO. CSIRO based drug effective against bird flu [online]. Available from URL: http://www.csiro.au/index.asp7.type=mediaRelease&docid=PrBird-Flu5&style=mediaRelease [Accessed 2004 Feb 20]
  • 48.CDC. Update on Influenza A(H5N1) and SARS: interim recommendations for enhanced US surveillance, testing, and infection control [online]. Available from URL: http://www.cdc.gov/flu/han020302.htm [Accessed 2004 Feb 12]
  • 49.Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet. 2004;363:617–9. doi: 10.1016/S0140-6736(04)15595-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Kuiken T, Rimmelzwaan GF, Van Amerongen G, et al. Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis) Vet Pathol. 2003;40:304–10. doi: 10.1354/vp.40-3-304. [DOI] [PubMed] [Google Scholar]
  • 51.Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999;282:31–5. doi: 10.1001/jama.282.1.31. [DOI] [PubMed] [Google Scholar]
  • 52.Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families: Zanamivir Family Study Group. N Engl J Med. 2000;343:1282–9. doi: 10.1056/NEJM200011023431801. [DOI] [PubMed] [Google Scholar]
  • 53.Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis. 2002;186:1582–8. doi: 10.1086/345722. [DOI] [PubMed] [Google Scholar]
  • 54.Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine- resistant influenza A in a nursing home. Infect Control Hosp Epidemiol. 2000;21:700–4. doi: 10.1086/501727. [DOI] [PubMed] [Google Scholar]
  • 55.Hayden FG, Jennings L, Robson R, et al. Oral oseltamivir in human experimental influenza B infection. Antivir Ther. 2000;5:205–13. [PubMed] [Google Scholar]
  • 56.Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341:1336–43. doi: 10.1056/NEJM199910283411802. [DOI] [PubMed] [Google Scholar]
  • 57.Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285:748–54. doi: 10.1001/jama.285.6.748. [DOI] [PubMed] [Google Scholar]
  • 58.Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can Commun Dis Rep. 2001;27:37–40. [PubMed] [Google Scholar]
  • 59.Peters PHJ, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001;49:1025–31. doi: 10.1046/j.1532-5415.2001.49204.x. [DOI] [PubMed] [Google Scholar]
  • 60.McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors: a review. Antiviral Res. 2000;47:1–17. doi: 10.1016/S0166-3542(00)00103-0. [DOI] [PubMed] [Google Scholar]
  • 61.Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 2001;49:147–56. doi: 10.1016/S0166-3542(01)00124-3. [DOI] [PubMed] [Google Scholar]
  • 62.Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998;178:1257–62. doi: 10.1086/314440. [DOI] [PubMed] [Google Scholar]
  • 63.Abed Y, Bourgault AM, Fenton RJ, et al. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J Infect Dis. 2002;186:1074–80. doi: 10.1086/344237. [DOI] [PubMed] [Google Scholar]
  • 64.McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother. 1996;40:40–6. doi: 10.1128/aac.40.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Matrosovich M, Matrosovich T, Carr J, et al. Overexpression of the alpha-2,6-si-alyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol. 2003;77:8418–25. doi: 10.1128/JVI.77.15.8418-8425.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Varghese JN, Smith PW, Sollis SL, et al. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure. 1998;6:735–46. doi: 10.1016/S0969-2126(98)00075-6. [DOI] [PubMed] [Google Scholar]
  • 67.Jackson HC, Roberts N, Wange ZM, et al. Management of influenza: use of new antivirals and resistance in perspective. Clin Drug Invest. 2000;20:447–54. doi: 10.2165/00044011-200020060-00007. [DOI] [Google Scholar]
  • 68.Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol. 2003;41:742–50. doi: 10.1128/JCM.41.2.742-750.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Molla A, Kati W, Carrick R, et al. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J Virol. 2002;76:5380–6. doi: 10.1128/JVI.76.11.5380-5386.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Gubareva LV, Bethell R, Hart GJ, et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol. 1996;70:1818–27. doi: 10.1128/jvi.70.3.1818-1827.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug- resistant influenza A virus in an immunocompromised patient. N Engl J Med. 2003;348:867–8. doi: 10.1056/NEJM200302273480923. [DOI] [PubMed] [Google Scholar]
  • 72.Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 2004;103:199–203. doi: 10.1016/j.virusres.2004.02.034. [DOI] [PubMed] [Google Scholar]
  • 73.Herlocher ML, Carr J, Ives J, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 2002;54:99–111. doi: 10.1016/S0166-3542(01)00214-5. [DOI] [PubMed] [Google Scholar]
  • 74.Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002;55:307–17. doi: 10.1016/S0166-3542(02)00053-0. [DOI] [PubMed] [Google Scholar]
  • 75.Herlocher ML, Truscon R, Elias S, et al. Transmission studies in ferrets of influenza viruses resistant to the antiviral oseltamivir. J Infect Dis. 2004;190(9):1627–30. doi: 10.1086/424572. [DOI] [PubMed] [Google Scholar]
  • 76.Vogel GE. Neuraminidase inhibitors in the management of influenza: experience of an outpatient practice. Med Microbiol Immunol (Berl) 2002;191:161–3. doi: 10.1007/s00430-002-0138-x. [DOI] [PubMed] [Google Scholar]
  • 77.Puhakka T, Lehti H, Vainionpaa R, et al. Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis. 2003;35:52–8. doi: 10.1080/0036554021000026981. [DOI] [PubMed] [Google Scholar]
  • 78.Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med. 2002;113:300–7. doi: 10.1016/S0002-9343(02)01222-6. [DOI] [PubMed] [Google Scholar]
  • 79.Da Silva PR, Nguyen VT, Hayward AC. Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care. J R Soc Med. 2003;96:66–9. doi: 10.1258/jrsm.96.2.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Webster A, Boyce M, Edmundson S, et al. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet. 1999;36(Suppl.1):51–8. doi: 10.2165/00003088-199936001-00006. [DOI] [PubMed] [Google Scholar]
  • 81.Cox RJ, Mykkeltvedt E, Sjursen H, et al. The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine. 2001;19:4743–9. doi: 10.1016/S0264-410X(01)00219-5. [DOI] [PubMed] [Google Scholar]

Articles from Treatments in Respiratory Medicine are provided here courtesy of Nature Publishing Group

RESOURCES